Q2 2019 Earnings Forecast for Millendo Therapeutics Inc (MLND) Issued By Svb Leerink

Millendo Therapeutics Inc (NASDAQ:MLND) – Research analysts at Svb Leerink cut their Q2 2019 earnings estimates for Millendo Therapeutics in a research report issued to clients and investors on Wednesday, May 15th. Svb Leerink analyst J. Schwartz now anticipates that the company will earn ($0.81) per share for the quarter, down from their previous estimate of ($0.76). Svb Leerink also issued estimates for Millendo Therapeutics’ Q3 2019 earnings at ($0.84) EPS, Q4 2019 earnings at ($0.86) EPS, FY2019 earnings at ($3.29) EPS, FY2020 earnings at ($3.39) EPS, FY2021 earnings at ($3.57) EPS and FY2022 earnings at ($3.30) EPS.

Millendo Therapeutics (NASDAQ:MLND) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.08). Millendo Therapeutics had a negative return on equity of 52.20% and a negative net margin of 10,128.37%.

MLND has been the subject of several other research reports. Jefferies Financial Group began coverage on shares of Millendo Therapeutics in a report on Wednesday, March 13th. They set a “buy” rating and a $22.00 price objective for the company. ValuEngine downgraded shares of Millendo Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 2nd. Finally, Zacks Investment Research raised shares of Millendo Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a report on Thursday, April 4th. Five investment analysts have rated the stock with a buy rating, Millendo Therapeutics currently has an average rating of “Buy” and an average target price of $23.25.

MLND opened at $16.32 on Monday. Millendo Therapeutics has a 52 week low of $6.77 and a 52 week high of $17.34. The stock has a market cap of $217.72 million, a price-to-earnings ratio of -0.93 and a beta of 3.30. The company has a quick ratio of 8.50, a current ratio of 7.83 and a debt-to-equity ratio of 0.02.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Morgan Stanley boosted its holdings in shares of Millendo Therapeutics by 749.4% during the 1st quarter. Morgan Stanley now owns 3,041 shares of the company’s stock valued at $46,000 after purchasing an additional 2,683 shares during the last quarter. Citigroup Inc. boosted its holdings in shares of Millendo Therapeutics by 6,052.5% during the 1st quarter. Citigroup Inc. now owns 6,091 shares of the company’s stock valued at $91,000 after purchasing an additional 5,992 shares during the last quarter. Geode Capital Management LLC bought a new position in shares of Millendo Therapeutics during the 4th quarter valued at about $113,000. Private Advisors LLC boosted its holdings in shares of Millendo Therapeutics by 9.1% during the 1st quarter. Private Advisors LLC now owns 15,263 shares of the company’s stock valued at $229,000 after purchasing an additional 1,279 shares during the last quarter. Finally, Tibra Equities Europe Ltd bought a new position in shares of Millendo Therapeutics during the 1st quarter valued at about $303,000. 42.53% of the stock is owned by institutional investors and hedge funds.

About Millendo Therapeutics

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Featured Article: Trading Stocks – What are percentage gainers?

Earnings History and Estimates for Millendo Therapeutics (NASDAQ:MLND)

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.